WNK2 and ovarian cancer: The antitumorigenic effects of this compound in ovarian cancer cells is exerted through inhibition of the phosphorylation of mitogen-activated protein kinase (MAPK) pathway elements like mitogen-activated protein kinase kinase (MEK) and extracellular-signal-regulated kinase (ERK) [47].